FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013194808> ?p ?o ?g. }

• W2013194808 endingPage "994" @default.
• W2013194808 startingPage "988" @default.
• W2013194808 abstract "Expression of multidrug resistance (MDR) features by acute myeloid leukemia (AML) cells predicts a poor response to many treatments. The MDR phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML. Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD33 antibody linked to calicheamicin, is effective monotherapy for CD33+ relapsed AML. However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined. In this study, blast cell samples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for Pgp surface expression and Pgp function using a dye efflux assay. In most cases, surface expression of Pgp correlated with Pgp function, as indicated by elevated dye efflux that was inhibited by CSA. Among samples from patients who either failed to clear marrow blasts or failed to achieve remission, 72% or 52%, respectively, exhibited CSA-sensitive dye efflux compared with 29% (P = .003) or 24% (P &lt; .001) among samples from responders. In vitro gemtuzumab ozogamicin–induced apoptosis was also evaluated using an annexin V–based assay. Low levels of drug-induced apoptosis were associated with CSA-sensitive dye efflux, whereas higher levels correlated strongly with achievement of remission and marrow blast clearance. In vitro drug-induced apoptosis could be increased by CSA in 14 (29%) of 49 samples exhibiting low apoptosis in the absence of CSA. Together, these findings indicate that Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials combining gemtuzumab ozogamicin with MDR reversal agents are warranted." @default.
• W2013194808 created "2016-06-24" @default.
• W2013194808 creator A5021879267 @default.
• W2013194808 creator A5023949296 @default.
• W2013194808 creator A5030413534 @default.
• W2013194808 creator A5031662456 @default.
• W2013194808 creator A5035557098 @default.
• W2013194808 creator A5042914371 @default.
• W2013194808 creator A5050992845 @default.
• W2013194808 creator A5056405520 @default.
• W2013194808 creator A5065804627 @default.
• W2013194808 creator A5089969677 @default.
• W2013194808 date "2001-08-15" @default.
• W2013194808 modified "2023-10-17" @default.
• W2013194808 title "Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin" @default.
• W2013194808 cites W1562680005 @default.
• W2013194808 cites W1706395004 @default.
• W2013194808 cites W1842764967 @default.
• W2013194808 cites W1916631802 @default.
• W2013194808 cites W1960701671 @default.
• W2013194808 cites W1983266647 @default.
• W2013194808 cites W2018639865 @default.
• W2013194808 cites W2066108808 @default.
• W2013194808 cites W2081507321 @default.
• W2013194808 cites W2165077627 @default.
• W2013194808 cites W2178680838 @default.
• W2013194808 cites W2228456847 @default.
• W2013194808 cites W2301875097 @default.
• W2013194808 cites W2322652491 @default.
• W2013194808 cites W2328129778 @default.
• W2013194808 cites W2335659822 @default.
• W2013194808 cites W2421335037 @default.
• W2013194808 cites W2764775166 @default.
• W2013194808 cites W3082443879 @default.
• W2013194808 cites W4238829088 @default.
• W2013194808 cites W4312790597 @default.
• W2013194808 cites W4322697658 @default.
• W2013194808 cites W77471785 @default.
• W2013194808 doi "https://doi.org/10.1182/blood.v98.4.988" @default.
• W2013194808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11493443" @default.
• W2013194808 hasPublicationYear "2001" @default.
• W2013194808 type Work @default.
• W2013194808 sameAs 2013194808 @default.
• W2013194808 citedByCount "187" @default.
• W2013194808 countsByYear W20131948082012 @default.
• W2013194808 countsByYear W20131948082013 @default.
• W2013194808 countsByYear W20131948082014 @default.
• W2013194808 countsByYear W20131948082015 @default.
• W2013194808 countsByYear W20131948082016 @default.
• W2013194808 countsByYear W20131948082017 @default.
• W2013194808 countsByYear W20131948082018 @default.
• W2013194808 countsByYear W20131948082019 @default.
• W2013194808 countsByYear W20131948082020 @default.
• W2013194808 countsByYear W20131948082021 @default.
• W2013194808 countsByYear W20131948082022 @default.
• W2013194808 countsByYear W20131948082023 @default.
• W2013194808 crossrefType "journal-article" @default.
• W2013194808 hasAuthorship W2013194808A5021879267 @default.
• W2013194808 hasAuthorship W2013194808A5023949296 @default.
• W2013194808 hasAuthorship W2013194808A5030413534 @default.
• W2013194808 hasAuthorship W2013194808A5031662456 @default.
• W2013194808 hasAuthorship W2013194808A5035557098 @default.
• W2013194808 hasAuthorship W2013194808A5042914371 @default.
• W2013194808 hasAuthorship W2013194808A5050992845 @default.
• W2013194808 hasAuthorship W2013194808A5056405520 @default.
• W2013194808 hasAuthorship W2013194808A5065804627 @default.
• W2013194808 hasAuthorship W2013194808A5089969677 @default.
• W2013194808 hasBestOaLocation W20131948081 @default.
• W2013194808 hasConcept C10205521 @default.
• W2013194808 hasConcept C126322002 @default.
• W2013194808 hasConcept C159654299 @default.
• W2013194808 hasConcept C176290653 @default.
• W2013194808 hasConcept C200082930 @default.
• W2013194808 hasConcept C203014093 @default.
• W2013194808 hasConcept C2778245361 @default.
• W2013194808 hasConcept C2778556491 @default.
• W2013194808 hasConcept C2778623314 @default.
• W2013194808 hasConcept C2778729363 @default.
• W2013194808 hasConcept C2780670749 @default.
• W2013194808 hasConcept C28328180 @default.
• W2013194808 hasConcept C502942594 @default.
• W2013194808 hasConcept C542903549 @default.
• W2013194808 hasConcept C54355233 @default.
• W2013194808 hasConcept C553184892 @default.
• W2013194808 hasConcept C55493867 @default.
• W2013194808 hasConcept C71924100 @default.
• W2013194808 hasConcept C86803240 @default.
• W2013194808 hasConcept C88634738 @default.
• W2013194808 hasConcept C98274493 @default.
• W2013194808 hasConceptScore W2013194808C10205521 @default.
• W2013194808 hasConceptScore W2013194808C126322002 @default.
• W2013194808 hasConceptScore W2013194808C159654299 @default.
• W2013194808 hasConceptScore W2013194808C176290653 @default.
• W2013194808 hasConceptScore W2013194808C200082930 @default.
• W2013194808 hasConceptScore W2013194808C203014093 @default.
• W2013194808 hasConceptScore W2013194808C2778245361 @default.
• W2013194808 hasConceptScore W2013194808C2778556491 @default.
• W2013194808 hasConceptScore W2013194808C2778623314 @default.

• next